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Abstract
The objective of this study was to identify intravascular ultrasound (IVUS), angiographic and metabolic parameters related to 
restenosis in patients with dysglycemia. Seventy consecutive patients (77 lesions) selected according to inclusion and exclusion 
criteria were evaluated by the oral glucose tolerance test and the determination of insulinemia after a successful percutane-
ous coronary intervention (PCI) with a bare-metal stent. The degree of insulin resistance was calculated by the homeostasis 
model assessment of insulin resistance (HOMA-IR). Six-month IVUS and angiogram follow-up were performed. Thirty-nine 
patients (55.7%) had dysglycemia. The restenosis rate in the dysglycemic group was 37.2 vs 23.5% in the euglycemic group 
(P = 0.299). The predictors of restenosis using bivariate analysis were reference vessel diameter (RVD): ≤2.93 mm (RR = 0.54; 
95%CI = 0.05-0.78; P = 0.048), stent area (SA): <8.91 mm2 (RR = 0.66; 95%CI = 0.24-0.85; P = 0.006), stent volume (SV): 
<119.75 mm3 (RR = 0.74; 95%CI = 0.38-0.89; P = 0.0005), HOMA-IR: >2.063 (RR = 0.44; 95%CI = 0.14-0.64; P = 0.027), and 
fasting plasma glucose (FPG): ≤108.8 mg/dL (RR = 0.53; 95%CI = 0.13-0.75; P = 0.046). SV was an independent predictor of 
restenosis by multivariable analysis. Dysglycemia is a common clinical condition in patients submitted to PCI. The degree of 
insulin resistance, FPG, RVD, SA, and SV were correlated with restenosis. SV was inversely correlated with an independent 
predictor of restenosis in patients treated with a bare-metal stent.
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Diabetes mellitus (DM) has been associated with poor 
clinical outcome and higher restenosis rate after percu-
taneous coronary intervention (PCI) using balloon alone, 
bare-metal stents (BMS) or drug-eluting stents (DES) (1-3). 
Although, on the basis of such evidence, DM has emerged 
as an independent predictor of restenosis, the mechanism 
responsible for this association remains to be elucidated 
(1-4). Several factors related to DM may be involved in the 
restenotic process: the duration of disease, the sustained 
hyperglycemic state, the requirement of insulin for control 
of plasma glucose concentration, the hyperinsulinemic 
condition of patients whose pancreatic β cell reserve is 
preserved, inflammation injury, and abnormal growth factors 
leading to neo-intimal proliferation (5,6). A strong correlation 
between pre-diabetic hyperglycemic states and increased 
cardiovascular risk has also been demonstrated (7). In ad-
dition, there is evidence that postprandial 2-h glycemia is 
better than fasting glycemia as a predictor to cardiovascular 
events (8,9). However, the role of insulin resistance (IR) 
in the development of cardiovascular disease is not well 
defined (10,11) despite the fact that IR is present in pre-
diabetic states such as impaired glucose tolerance (IGT) 
or impaired fasting glycemia (IFG) (12). The role of these 
pre-diabetic hyperinsulinemic states in the development 
of restenosis after PCI is even less understood, although 
a direct correlation of neo-intimal hyperplasia after PCI 
and IR has been suggested (13-16). Therefore, the aim 
of the present study was to correlate glucose metabolism 
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parameters with intravascular ultra-sound (IVUS) and 
quantitative coronary angiographic (QCA) characteristics 
of restenosis in a population of non-selected consecutive 
patients undergoing PCI with BMS.
Material and Methods
Study population
This was a prospective, single-center controlled cohort 
study designed to correlate the glycemic metabolic status of 
patients submitted to PCI using BMS with QCA and IVUS 
data. During a period of 18 months, from January 2001 to 
August 2002, we studied 76 consecutive patients selected 
according to strict inclusion and exclusion criteria with 84 
lesions who were enrolled in this study after a successful 
procedure. The study was approved by the Institutional 
Review Board and all patients gave written informed consent 
after appropriate consideration of inclusion and exclusion 
criteria. 
Procedure-related parameters such as number of stents, 
final pressure of deployment and type of stent were left to 
the discretion of the operators. All patients received com-
bined anti-platelet therapy with acetylsalicylic acid and a 
thienopyridine for at least 1 month after the procedure. Gly-
coprotein IIb/IIIa inhibitors were not used in any patient.
Within 2 weeks after a successful PCI documented with 
QCA and IVUS, the patients were evaluated for glycemic 
metabolism. The patients were monitored during a 6-month 
follow-up period by visits at 30 days, 3 and 6 months, and 
coronary angiography and IVUS were repeated after this 
period in all but 6 patients. The data presented concern 70 
patients (77 lesions) who completed the study.
Inclusion and exclusion criteria
Consecutive patients ≥18 years old referred for PCI on 
the basis of having clinical and/or laboratory evidence of 
myocardial ischemia, with at least one coronary stenosis 
≥70% in vessels with a reference diameter >2.5 mm, were 
considered eligible to participate in the study. The other sine-
qua-non criterion was to provide a signed informed consent 
for participating in the study protocol. The exclusion criteria 
were as follows: non-protected left main coronary stenosis, 
angiographic evidence of coronary thrombus, degenerated 
saphenous vein graft lesions, total occlusions, pregnancy, 
acute phase of a coronary syndrome. 
Metabolic evaluation
The patients underwent an oral glucose tolerance test 
(OGTT) with assessment of glycemia and insulinemia at 
baseline and 2 h after glucose ingestion. The degree of 
insulin resistance was evaluated by the homeostasis model 
assessment method (HOMA-IR) (17).
After metabolic evaluation, 39 patients (55.7%) with 
43 lesions were found to be dysglycemic and 31 patients 
(44.3%) with 34 lesions were found to be euglycemic. The 
dysglycemic group comprised 23 diabetic patients with 27 
lesions, and 16 patients with IGT and/or IFG with 16 lesions. 
The OGTT was not performed in 4 diabetic patients because 
they were under treatment with insulin (2 patients) or with 
double-oral hypoglycemic drugs (2 patients).
The criterion for the diagnosis of IFG was fasting plasma 
glucose (FPG) ≥100.0 mg/dL (5.6 mM), but <126 mg/dL (7.0 
mM). An IGT state was characterized by FPG <126 mg/
dL (7.0 mM) with 2-h glycemia ≥140 mg/dL (7.8 mM) and 
<200 mg/dL (11.1 mM). The individuals were considered 
to be diabetic if their FPG was ≥126 mg/dL and/or a 2-h 
glycemia >200 mg/dL.
Study endpoints
The primary endpoint was the comparison of angiog-
raphy restenosis rates between the subgroups of patients 
with dysglycemia and euglycemia. The secondary endpoint 
was the correlation of the occurrence of restenosis as de-
termined by the binary angiographic criteria with the IVUS, 
QCA and metabolic parameters. 
Angiographic and IVUS analysis
Patients were submitted to an angiogram and IVUS im-
mediately and 6 months after the procedure. The QCA and 
IVUS analyses were performed by experienced observers 
who were blind to the metabolic status of the patients.
QCA was performed off-line using a previously validated 
(18) edge-detection system, the CAAS-II System (Pie Medi-
cal Imaging B.V., Netherlands). The analysis was performed 
using the standard methodology, in a frame corresponding 
to the diastolic phase of the cardiac cycle, in two orthogonal 
projections, identical at baseline, post-procedure, and at the 
6-month follow-up. The following parameters were analyzed: 
reference vessel diameter (RVD), minimum luminal diam-
eter, lesion length, and percent stenosis (stenosis).
The IVUS studies were performed using commercially 
available systems, Clear View™ or Galaxy™ (Boston Sci-
entific, USA), and catheters with 30- or 40-MHz transducers. 
An automatic IVUS pullback from a position distal to the 
stent toward the aorto-ostial junction was performed at a 
speed of 0.5 mm/s, following the intracoronary administra-
tion of 200 µg nitroglycerin.
The quantitative analysis of IVUS was performed 
according to the criteria established in the clinical expert 
consensus document of the American College of Cardiol-
ogy, and volumetric analysis was performed using Symp-
son’s rule (19). The following parameters were evaluated: 
minimum lumen area (MLA), stent area (SA) at the site 
of MLA (mm2), and neointimal hyperplasia area (NHA) in 
mm2; lumen volume, stent volume (SV), and neointimal 
hyperplasia volume (NHV) in mm3; and NHV/SV and NHA/
SA as percent. The PCI procedures were not guided by 
IVUS but were documented by IVUS, although in one 
case a large area of stent underexpansion was observed 
by IVUS, leading to an additional balloon dilation followed 
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by a new and final IVUS pullback.
Follow-up
A clinical follow-up evaluation was performed 1, 3, 
and 6 months after the procedure. At the 6-month visit, a 
new angiogram with IVUS evaluation was scheduled and 
performed up to 2 weeks thereafter. Of the 76 patients 
previously enrolled, 5 refused to be submitted to another 
procedure and 1 patient died from a cardiovascular com-
plication 3 months after the procedure. No further cardio-
vascular event was observed.
During the follow-up period, 2 patients were receiving 
insulin, 2 metformin plus glibenclamide, 4 only metformin, 
6 only glibenclamide, and none was receiving rosiglitazone. 
All diabetic patients were receiving statins. 
Statistical analysis
Sample size calculation. Previous studies have ob-
served a difference in the area of neointimal hyperplasia of 
64%, with SD = 42 and 95%CI = 32-90 in the comparison 
of diabetic vs non-diabetic patients and a difference of 
35% with SD = 28 and 95%CI = 7-52 in the comparison of 
glucose-intolerant vs normoglycemic individuals. Based on 
these results, in order to detect a difference of 35% between 
normoglycemics and dysglycemics and of 60% between 
normoglycemics and diabetics, with 80 or 90% power, we 
would need 15 to 25 subjects per group, respectively, using 
a t-test and a two-sided level of significance.
Continuous variables are reported as means ± SD and 
were analyzed for significant differences between dysglyce-
mic and euglycemic individuals, and also between patients 
with and without restenosis using the Student t-test or the 
Mann-Whitney test. Categorical variables were analyzed 
for significant differences using the chi-square test and 
the Fisher exact test. Linear regression and Spearman 
or Pearson correlation estimates were used. One-way 
analysis of variance was used to determine the clinical 
and laboratory parameters related to a greater degree of 
neointimal hyperproliferation. The predictors of restenosis 
were evaluated by bivariate analysis, correlating the binary 
criteria of restenosis with the median or 75th percentile of 
any continuous variable. All variables with a P value ≤0.05 
were also evaluated by multiple logistic regression analysis. 
A P value ≤0.05 was considered to be significant.
Results
Comparisons of euglycemic versus dysglycemic 
individuals
There were no significant differences regarding clinical 
baseline characteristics between the two groups (Table 1). 
Lesions in the left circumflex artery were more prevalent in 
dysglycemic patients. No other significant difference was 
observed regarding the baseline angiogram characteristics, 
QCA parameters, or procedural results (Table 2). Similar 
results were observed regarding the IVUS and QCA pa-
rameters at the 6-month follow-up (Table 3).
The rate of restenosis in the dysglycemic group was 
37.2% (16 of 43 lesions) versus 23.5% in the euglycemic 
group (8 of 34 lesions), but this 37% difference in restenosis 
was not statistically significant (P = 0.299). 
When we subdivided the dysglycemic patient group 
Table 1. Baseline clinical characteristics of the patients studied.
Dysglycemic Euglycemic
Total 39 (55.7%) 31 (44.3%)
BMI (means ± SD) 27.3 ± 4.9 25.8 ± 3.0
Age [years (range)] 64 (47-78) 61 (40-85)
Male gender 29 (74.4%) 25 (80.6%)
Asymptomatic 7 (17.9%) 1 (3.2%)
Stable 9 (23.1%) 7 (22.6%)
ACS 23 (59.0%) 23 (74.2%)
Hypertension 34 (87.2%) 23 (74.2%)
Obesity 13 (33.3%) 3 (9.7%)
Dyslipidemia 26 (66.6%) 14 (45.2%)
Family history 17 (43.6%) 13 (41.9%)
Tobacco use 13 (33.3%) 8 (25.8%)
LVEF <0.50 12 (30.7%) 3 (9.7%)
1-Vessel disease 16 (41.0%) 16 (51.6%)
2-Vessel disease 17 (43.6%) 12 (38.7%)
3-Vessel disease 6 (15.4%) 3 (9.7%)
Data are reported as number with percent in parentheses unless 
otherwise indicated. ACS = acute coronary syndrome; LVEF = 
left ventricle eject fraction. There were no statistically significant 
differences between the groups for any parameter (chi-square 
and Mann-Whitney tests).
Table 2. Procedural characteristics and quantitative coronary 
angiographic parameters. 
Dysglycemic Euglycemic
LAD/RCA/LCX (%) 37/35/28 58/35/7*
Maximal inflation pressure (atm) 15.3 ± 2.0 14.9 ± 2.0
Stent length (mm) 13.9 ± 4.8 12.5 ± 3.8
RVD - baseline (mm) 2.99 ± 0.50 2.82 ± 0.50
MLD - baseline (mm) 0.84 ± 0.26 0.80 ± 0.33
Stenosis (%) - baseline 71.4 ± 8.7 71.3 ± 10.5
Lesion length - baseline (mm) 11.8 ± 4.2 11.0 ± 3.3
RVD - post-PCI (mm) 3.24 ± 0.46 3.09 ± 0.39
MLD - post-PCI (mm) 2.74 ± 0.39 2.61 ± 0.36
Stenosis (%) - post-PCI 15.8 ± 6.1 15.1 ± 6.3
Data are reported as means ± SD. LAD = left anterior descen-
dent; RCA = right coronary artery; LCX = left circumflex; RVD = 
reference vessel diameter; MLD = minimum luminal diameter; 
PCI = percutaneous coronary intervention. *P = 0.041 compared 
to dysglycemic patients (Fischer exact test and Student t-test).
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according to the presence of DM or IGT we observed a 
restenosis rate of 44.4% (12 of 27 lesions) in diabetic 
patients versus 25% (4 of 16 lesions) in IGT patients, a 
difference that was not statistically significant.
Comparison of restenotic versus non-restenotic 
groups
In an attempt to establish whether any metabolic, angio-
graphic or IVUS parameter would influence the incidence of 
restenosis, we compared patients regarding the presence 
or absence of restenosis. A statistically significant differ-
ence was observed between restenotic and non-restenotic 
lesions in IVUS parameters correlated to vessel dimen-
sions such as SV: 90.0 ± 50.5 vs 142.01 ± 67.29 mm3, P 
= 0.0003, and SA: 7.53 ± 2.23 vs 10.04 ± 2.65 mm2, P = 
0.0003. Similarly, by QCA analysis, RVD was found to be 
significantly smaller in the group with restenosis compared 
to the group with non-restenotic lesions, 2.64 ± 0.46 vs 2.96 
± 0.51 mm, P = 0.0102.
It is interesting to note that the MLA at follow-up cor-
related strongly with the SA (Figure 1). The patients with 
restenosis had significantly higher rates of IR as determined 
by HOMA-IR and more elevated values of postprandial 
glycemia. They also tended to have higher FPG and 2-h 
insulinemia (Table 4).
The predictors of coronary restenosis using bivariate 
analysis for the whole group were RVD: ≤2.93 mm (sample 
median), RR = 0.54 (95%CI = 0.05-0.78), P = 0.048; SA: 
<8.91 mm2 (sample median), RR = 0.66 (95%CI = 0.24-
0.85), P = 0.006; SV: <119.75 mm3 (sample median), 
RR = 0.74 (95%CI = 0.38-0.89), P = 0.0005; HOMA-IR: 
>2.063 (sample median), RR = 0.44 (95%CI = 0.14-0.64), 
P = 0.027, and FPG: ≤108.8 mg/dL (sample median), RR 
= 0.53 (95%CI = 0.13-0.75), P = 0.046 (Table 5). Only SV 
remained as independent predictor of restenosis by the 
multiple linear regression analysis (Table 6).
Figure 1. Relation between minimum lumen area and stent area 
measured by intravascular ultrasound at 6 months of follow-up 
(FU).
Table 3. Intravascular ultrasound and quantitative coronary an-
giographic parameters at 6-month follow-up.
 Dysglycemic Euglycemic
Lumen area (mm2) 4.40 ± 2.72 4.15 ± 2.18
Stent area (mm2) 9.38 ± 2.97 9.06 ± 2.54
Neointimal hyperplasia area (mm2) 4.98 ± 1.94 4.90 ± 1.45
NHA/SA (%) 55.4 ± 16.8 56.0 ± 14.6
Lumen volume (mm3) 87.8 ± 61.3 67.5 ± 38.9
Stent volume (mm3) 137.3 ± 76.3 110.2 ± 48.9
Neointimal hyperplasia volume (mm3) 49.5 ± 28.3 42.7 ± 21.0
NHV/SV (%) 39.5 ± 18.1 41.1 ± 15.7
Reference vessel diameter (mm) 2.95 ± 0.58 2.75 ± 0.40
Minimum luminal diameter (mm) 1.71 ± 0.77 1.71 ± 0.62
Stenosis (%) 44.1 ± 19.6 38.7 ± 19.2
Late loss 0.91 ± 0.63 1.04 ± 0.65
Data are reported as means ± SD. NHA/SA = neointimal hyper-
plasia area/stent area; NHV/SV = neointimal hyperplasia volume/
stent volume. There were no statistically significant differences 
between the groups for any parameter (Student t-test).
Table 4. Comparison of the metabolic parameters of the groups 
with and without restenosis.
 Restenosis No restenosis
HOMA-IR 3.7 ± 3.0 2.9 ± 3.4*
Insulin (µU/mL), fasting 11.5 ± 6.0 10.4 ± 8.2
Glycemia (mg/dL), fasting 125.7 ± 66.1 98.0 ± 31.0
Insulin (µU/mL), 120 min 110.8 ± 71.2 83.3 ± 63.9
Glycemia (mg/dL), 120 min 184.8 ± 90.2 147.2 ± 72.2*
Data are reported as means ± SD. HOMA-IR = homeostasis 
model assessment of insulin resistance. *P < 0.05 compared to 
restenosis (Student t-test).
Table 5. Predictors of restenosis - bivariate analysis.
Relative risk P
Fasting glycemia <108.0 mg/dLa 0.53 (0.13-0.75) 0.046
Glycemia - 120 min <183.5 mg/dLa 0.45 (0.04-0.71) 0.093
Fasting insulin <13.0 µU/mLa 0.28 (0.41-0.63) 0.679
Insulin - 120 min ≥78.0 µU/mLb 0.45 (0.04-0.71) 0.093
HOMA-IR <2.06a 0.44 (0.14-0.64) 0.027
RVD ≥2.82 mma 0.60 (0.15-0.81) 0.014
Stent volume ≥119.8 mm3a 0.74 (0.38-0.89) 0.0005
Stent area ≥8.91 mm2a 0.66 (0.24-0.85) 0.006
HOMA-IR = homeostasis model assessment of insulin resis-
tance; RVD = reference vessel diameter. aMedian value; b75th 
percentile value.
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Discussion
Although DM, IGT and IFG are associated with increased 
cardiovascular risk, the assessment of glucose metabolism 
is commonly neglected in many patients treated with PCI 
(8,9). In a cohort of 1612 patients, 61% of them were found 
to have diabetes or pre-diabetes (20). Similarly, the present 
study showed that 55.7% of consecutive patients being 
treated with PCI had dysglycemia. However, our investi-
gation differs from that seminal study by the fact that we 
performed an OGTT and the criterion for IFG was updated 
according to the last ADA Expert Document Consensus 
(FPG ≥100 mg/dL) (21). The stricter criterion for defining 
patients with IFG used in our study was justified by the fact 
that, although a tighter glycemic control has been shown 
to be effective in the prevention of microvascular disease 
in diabetic and pre-diabetic patients, no similar clear rela-
tion has been established regarding the development of 
macrovascular atherosclerotic complications in this set of 
patients (22).
A correlation between glycated hemoglobin (HbA1c) 
levels and major adverse cardiac events after PCI has 
been shown in non-diabetic patients (23). However, in the 
cited study the patients were only considered diabetic if 
previously diagnosed or if they had HbA1c >7.0%, a crite-
rion not consistent with current standards (21). The same 
group of investigators also found a relationship between 
glycemic control and rate of restenosis, considering a level 
of HbA1c >7.0% as a parameter of uncontrolled DM (24). 
This observation was not confirmed by two recent studies 
that did not show a direct relationship between target lesion 
revascularization and other cardiac events after PCI and 
HbA1c levels (25,26). The present study, in which we actively 
established the diagnosis of both DM and pre-diabetes sta-
tus using currently accepted methodology (21,27), confirms 
and extends the results of these previous studies. Thus, 
by bivariate analysis, we observed a reduction in the risk 
of restenosis as defined by the binary criteria, when FPG 
≤108 mg/dL (median), RR = 0.53 (95%CI = 0.13-0.75), P 
= 0.046. These results are similar to those of Muhlestein 
et al. (20) who found a 3-fold increase in the risk of death 
during a follow-up of 2.8 ± 1.2 years after PCI when FPG 
exceeded 109 mg/dL.
In dysglycemic patients with either microvascular or 
macrovascular disease, the postprandial glycemia has been 
considered a better predictor of mortality than FPG (8,9). In 
our study, we observed a trend to a reduction of restenosis 
rate when the 120-min glycemia was <183.5 mg/dL. 
No direct or independent relation of IR to coronary artery 
disease has been established (10,11,28,29). Moreover, 
the relation of IR to restenosis is even more elusive be-
cause the few studies addressing this issue used different 
methodology, and the results were highly heterogeneous 
(13-16,30,31). For instance, an unexpected inverse relation-
ship between insulinemia levels and restenosis rate was 
described following excimer laser coronary angioplasty 
(30). Since fasting hyperinsulinemia is an unquestionable 
parameter of IR (32), there is no logical explanation for this 
finding. In our study, no differences in fasting insulinemia 
levels were found between the restenotic and non-restenotic 
groups; only a trend toward higher 120-min insulinemia 
levels was observed in the restenotic group. In the bivariate 
analysis, we observed that the degree of IR, as defined by 
an HOMA-IR <2.06, decreased the risk of restenosis, but 
multivariable analysis did not show an independent rela-
tionship between these variables. Our results agree with 
published data describing a relationship between greater 
neointimal index area (not measured with IVUS as in our 
study) and IR (16). Other studies also described a relation-
ship between restenosis and IR, but in most of them diabetic 
patients were excluded and no IVUS measurements were 
performed (13,15,31). In the only published study in which 
diabetic patients were included and a direct relationship be-
tween plasma insulin levels and restenosis was described, 
IVUS was not used, and, unexpectedly, QCA parameters 
related to vessel diameter were not considered to be pre-
dictors of restenosis (14). In our study, as in previous trials, 
RVD was a significant predictor of restenosis (4,33). We 
also observed that SA measured by IVUS was significantly 
and inversely related to the rate of restenosis. A minimal 
Table 6. Predictors of restenosis - multiple logistic regression analysis.
Beta coefficient Standard error Wald coeff./SE Prob Exp (beta)
HOMA-IR 2.71675 1.70828 1.59034 0.11 15.13
Fasting glycemia -2.1871 1.78436 -1.22571 0.22 0.1122
Stent volume 4.34938 1.76364 2.46615 0.013 77.43
Stent area 2.19828 1.87928 1.16975 0.24 9.01
RVD -0.85389 1.6749 -0.05982 0.96 0.9182
Constant -5.07521 2.4083 -2.10738 0.017 -
HOMA-IR = homeostasis model assessment of insulin resistance; RVD = reference ves-
sel diameter.
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stent area >6.5 mm2 determined by IVUS right after the 
procedure has been previously described to be associated 
with nearly 95% freedom from subsequent new target le-
sion revascularization at 9-month follow-up (34). The same 
group of investigators emphasized the importance of stent 
expansion through a sub-study of DES in the SIRIUS trial 
(35). The present findings fully agree with these data - the 
regression coefficient we observed lies exactly in the middle 
between the DES and BMS groups analyzed in the SIRIUS 
sub-study, but the cut-off points of minimal stent area were 
different, 8.91 vs 6.5 mm2 as predictors of restenosis. This 
might be partially explained by the fact that we considered 
the binary angiographic definition of restenosis, and those 
studies considered the need of new target lesion revascu-
larization (34) and an MLA <4.0 mm2 by IVUS follow-up 
(35) for the definition of restenosis.
The present study is the first to show that SV is an 
independent predictor of restenosis. IVUS parameters as 
predictors of restenosis were previously described in study 
with Palmaz-Schatz stents (36). In another study, a chart 
based on IVUS data from five trials was constructed, and 
by bivariate analysis SV was not considered to be a pre-
dictor of restenosis. Interestingly, by multivariable logistic 
regression analysis with multiple models containing two 
IVUS parameters, the SV associated with stent length were 
considered to be predictors of restenosis (37). It is impor-
tant to point out that in our study there was no significant 
difference between the groups with and without restenosis 
regarding stent length.
Among other characteristics, our study differs from the 
previous investigations in that we prospectively included 
consecutive patients, used eight different stent types, and 
eventually had more than 50% of our patients being at higher 
risk of restenosis based on their dysglycemic status.
Lesion length was similar in both groups, and the refer-
ence vessel diameter of dysglycemics was higher than that 
of the euglycemic group (without statistical significance). 
Since more than one third of dysglycemic patients were 
diabetics, these are unexpected findings, since diabetes 
mellitus is generally associated with longer lesions and 
smaller vessels. We do not have an explanation for this 
observation. But the same finding has been reported in 
most studies showing no difference in terms of vessel 
diameter when comparing diabetics and non-diabetics. 
Maybe this merely reflects screening bias since usually 
diabetic patients with small vessels and long lesions are 
not referred for PCI.
Recently, a meta-analysis showed a direct relationship 
between C-reactive protein and angiographic restenosis 
after bare-metal stent implantation (38). Also, a recent study 
(39) showed that both diabetic and non-diabetic patients 
exhibited an inflammatory response after PCI, expressed 
by C-reactive protein levels, and that the intensity of this 
reaction was more pronounced in diabetic patients. How-
ever, we have no data on inflammatory markers from our 
investigation. 
Finally, although in some countries the mainstay of PCI 
currently lies in the use of DES for diabetic patients, this is 
not the case in our country, mainly because of economic 
limitations. Moreover, a recent study using data from the 
National Heart, Lung and Blood Institute of Health showed 
that, in comparison to BMS, the use of DES had a positive 
impact on cardiac events in diabetic patients not receiv-
ing insulin, but not on those under insulin treatment (40). 
Hence, the present data are pertinent for the great majority 
of dysglycemic patients treated with bare-metal stents in 
this and other developing countries. 
Clinical implications
With current difficulties for a more widespread use of 
DES, the concept that larger reference and luminal diam-
eters may protect against the physiological consequences 
of neointimal hyperplasia is still valid, even in patients at 
higher risk of restenosis because of a dysglycemic status. 
Although the biologic variability of neointimal hyperplasia 
in the BMS restenosis process is influenced by metabolic 
status, its clinical impact mostly depends on procedural 
and anatomical factors. The same amount of neointimal 
hyperplasia may produce different clinical outcomes, basi-
cally depending on the vessel and stent diameters. Larger 
studies are necessary using new available technologies 
such as last generation DES in association with optimal 
medical therapy to resolve this issue.
Study limitations
This was a single-center study with a small sample. 
The metabolic parameters were evaluated only at baseline 
and did not include measurement of HbA1c or anti-inflam-
matory markers such as C-reactive protein levels. Hence, 
no information was obtained on how the glycemic status, 
a factor potentially influencing the restenosis process, 
was maintained during follow-up. In theory, the metabolic 
status of the patients could also have changed between 
the procedure and the time of the evaluation. However, 
the metabolic status of the patients was assessed within 2 
weeks following the index procedure. In fact, most patients 
were evaluated metabolically within the first week. Hence, 
we would not expect to observe a dramatic change in glyce-
mic metabolism within such a short period of time. Neither 
would we assume that the procedure itself could change 
the metabolic status of the patients, since there is not one 
single study showing a dysglycemic condition triggered by a 
cardiovascular event or percutaneous coronary intervention. 
Because we included patients with DM, the trend toward 
more restenosis among the patients with dysglycemia could 
have been driven by this well-known predictor. However, 
the fact that by bivariate analysis the fasting glycemia level 
correlated with the appearance of restenosis, supports the 
conclusion that less advanced dysglycemia conditions are 
indeed associated with this complication of PCI. Finally, 
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the IR was not evaluated using the gold-standard method, 
the hyperinsulinemic-euglycemic clamp technique, but this 
limitation probably would not have influenced the results 
of the study. 
We conclude that dysglycemia is a common clinical 
condition in patients submitted to PCI. After PCI using 
BMS, coronary restenosis tended to be more frequent in 
patients with dysglycemia compared to euglycemic patients. 
The degree of IR and the FPG levels correlated with the 
restenosis rate, but were not considered to be independent 
predictors of this complication. The stent dimensions, mea-
sured by both IVUS and QCA, were inverse determinants 
of restenosis rates. SV by IVUS was independently related 
to restenosis.
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